The poster will include clinical data as of an April 4, 2025 data cutoff from the Company's ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in ...

Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, ...

AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today announced that it will present a preclinical ...

Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today that it will present new data from five studies, ...

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program ...

Environment / Dispelling the myth that climate action is unpopular could push the world over a social tipping point and lead ...

It's all about finding a look that highlights your beauty. These expert-approved hairstyles for women over 40 will do just ...

TWO Demons have been offered financial sanctions following Melbourne’s Round 6 win over Fremantle at the MCG. Caleb Windsor and Kysaiah Pickett both caught the eye of the Match Review Officer on ...

On Thursday 24 April, one of the AFL’s most poignant traditions will take place—the Anzac Day Eve match between Melbourne and Richmond. Now in its tenth year, this powerful event has grown into far ...